Rocket Pharmaceuticals, Inc.

This was a clinical-update call rather than a financial earnings call, so no revenue, EPS, gross margin, or cash figures were reported in the transcript. For Danon disease, Rocket said it expects to resume the trial in Q3 after submitting all requested FDA changes and receiving agreement on the updated protocol. The company said it will no longer pursue the higher-dose range and will focus on the low dose, with more data from low- and higher-dose patients expected in Q4. Management also said the next Phase 2/registration discussion will depend on pediatric data, natural history work, and end-of-Phase-1 alignment with FDA.

Gaurav Shah emphasized that Rocket and FDA have been working collaboratively and that the Danon program now has clearer safety guardrails and refined eligibility criteria. He highlighted what he called increasing and durable low-dose benefit, including biopsy evidence of reduced vacuoles and improvements in BNP, cardiac output, six-minute walk test, and NYHA class. His tone was constructive and confident, especially around the decision to focus on the low dose and move rapidly toward Phase 1 completion and a Phase 2 registration study.

No CFO financial commentary was provided in the transcript, and no operating metrics or capital allocation updates were discussed. The only finance-related item was administrative: the company announced that Claudine Prowse would be transitioning out of Rocket to take a CFO role elsewhere. There were no cash, runway, or spending figures mentioned.

Analysts focused heavily on what still needs to happen before Danon can restart, whether the September advisory committee meeting could be affected, and how the high-dose discontinuation changes the program’s path. Management said the FDA has confirmed no further protocol comments for now, there is no reason to think the clinical hold affects the advisory committee timing, and the next Phase 2 is expected to be a single program spanning pediatrics and adolescents. Questions also probed the IMO patient death and potential risk factors; management said the trial is on a self-mandated pause under protocol, there was no myocarditis or inflammatory finding, and they will provide more comprehensive data later in the year.